{"id":"https://openalex.org/W2992248754","doi":"https://doi.org/10.1002/prp2.534","title":"Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice","display_name":"Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice","publication_year":2019,"publication_date":"2019-12-01","ids":{"openalex":"https://openalex.org/W2992248754","doi":"https://doi.org/10.1002/prp2.534","mag":"2992248754","pmid":"https://pubmed.ncbi.nlm.nih.gov/31832201","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6887677"},"language":"en","primary_location":{"id":"doi:10.1002/prp2.534","doi":"https://doi.org/10.1002/prp2.534","is_oa":true,"landing_page_url":"https://doi.org/10.1002/prp2.534","pdf_url":"https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prp2.534","source":{"id":"https://openalex.org/S2764487716","display_name":"Pharmacology Research & Perspectives","issn_l":"2052-1707","issn":["2052-1707"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology Research & Perspectives","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prp2.534","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5083743251","display_name":"Jason T. Anderson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason T. Anderson","raw_affiliation_strings":["Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077955893","display_name":"Shuiying Hu","orcid":"https://orcid.org/0000-0002-9806-7734","observed_orcids":["https://orcid.org/0000-0002-9806-7734"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shuiying Hu","raw_affiliation_strings":["Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101741566","display_name":"Qiang Fu","orcid":"https://orcid.org/0000-0003-2052-4824","observed_orcids":["https://orcid.org/0000-0003-2052-4824"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Qiang Fu","raw_affiliation_strings":["Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077260725","display_name":"Sharyn D. Baker","orcid":"https://orcid.org/0000-0003-3062-3252","observed_orcids":["https://orcid.org/0000-0003-3062-3252"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sharyn D. Baker","raw_affiliation_strings":["Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA"],"raw_orcid":"https://orcid.org/0000-0003-3062-3252","affiliations":[{"raw_affiliation_string":"Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065279964","display_name":"Alex Sparreboom","orcid":"https://orcid.org/0000-0003-2660-6644","observed_orcids":["https://orcid.org/0000-0003-2660-6644"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Alex Sparreboom","raw_affiliation_strings":["Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA"],"raw_orcid":"https://orcid.org/0000-0003-2660-6644","affiliations":[{"raw_affiliation_string":"Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA","institution_ids":["https://openalex.org/I52357470"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5065279964"],"corresponding_institution_ids":["https://openalex.org/I52357470"],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":{"value":2500,"currency":"USD","value_usd":2500},"fwci":0.8203,"has_fulltext":true,"cited_by_count":13,"citation_normalized_percentile":{"value":0.74379093,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":97},"biblio":{"volume":"7","issue":"6","first_page":"e00534","last_page":"e00534"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.9564999938011169,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.9564999938011169,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.018300000578165054,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12827","display_name":"Biochemical and Molecular Research","score":0.0044999998062849045,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":0.9869999885559082},{"id":"https://openalex.org/keywords/ent1","display_name":"equilibrative nucleoside transporter 1","score":0.9760000109672546},{"id":"https://openalex.org/keywords/drug-disposition","display_name":"drug disposition","score":0.593999981880188},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.8849999904632568},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9240000247955322},{"id":"https://openalex.org/keywords/nucleoside-transporters","display_name":"nucleoside transporters","score":0.8759999871253967},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9210000038146973},{"id":"https://openalex.org/keywords/octn1","display_name":"OCTN1","score":0.7360000014305115},{"id":"https://openalex.org/keywords/oatp1b2","display_name":"Oatp1b2","score":0.9959999918937683},{"id":"https://openalex.org/keywords/mate1","display_name":"MATE1","score":0.8980000019073486},{"id":"https://openalex.org/keywords/mice","display_name":"mice","score":0.3160000145435333}],"concepts":[{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.7605483531951904},{"id":"https://openalex.org/C149011108","wikidata":"https://www.wikidata.org/wiki/Q652985","display_name":"Transporter","level":3,"score":0.7165311574935913},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6800070405006409},{"id":"https://openalex.org/C2776844798","wikidata":"https://www.wikidata.org/wiki/Q34402","display_name":"Ribonucleoside","level":4,"score":0.6611560583114624},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.6449416875839233},{"id":"https://openalex.org/C2776543447","wikidata":"https://www.wikidata.org/wiki/Q28734","display_name":"Nucleoside","level":2,"score":0.633846640586853},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5621185302734375},{"id":"https://openalex.org/C38022665","wikidata":"https://www.wikidata.org/wiki/Q1149305","display_name":"Disposition","level":2,"score":0.5082857012748718},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4487978219985962},{"id":"https://openalex.org/C2780549722","wikidata":"https://www.wikidata.org/wiki/Q7068260","display_name":"Nucleoside transporter","level":4,"score":0.41760775446891785},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3467419743537903},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2006680965423584},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.15602251887321472},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.12176120281219482},{"id":"https://openalex.org/C67705224","wikidata":"https://www.wikidata.org/wiki/Q11053","display_name":"RNA","level":3,"score":0.08173492550849915},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.06257489323616028},{"id":"https://openalex.org/C77805123","wikidata":"https://www.wikidata.org/wiki/Q161272","display_name":"Social psychology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000964","descriptor_name":"Antimetabolites, Antineoplastic","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000964","descriptor_name":"Antimetabolites, Antineoplastic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013868","descriptor_name":"Thioinosine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D013868","descriptor_name":"Thioinosine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D018345","descriptor_name":"Mice, Knockout","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D027381","descriptor_name":"Liver-Specific Organic Anion Transporter 1","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D027381","descriptor_name":"Liver-Specific Organic Anion Transporter 1","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D027701","descriptor_name":"Organic Cation Transport Proteins","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D027701","descriptor_name":"Organic Cation Transport Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D027981","descriptor_name":"Symporters","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D027981","descriptor_name":"Symporters","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D033721","descriptor_name":"Equilibrative Nucleoside Transporter 1","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D033721","descriptor_name":"Equilibrative Nucleoside Transporter 1","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D033721","descriptor_name":"Equilibrative Nucleoside Transporter 1","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1002/prp2.534","doi":"https://doi.org/10.1002/prp2.534","is_oa":true,"landing_page_url":"https://doi.org/10.1002/prp2.534","pdf_url":"https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prp2.534","source":{"id":"https://openalex.org/S2764487716","display_name":"Pharmacology Research & Perspectives","issn_l":"2052-1707","issn":["2052-1707"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology Research & Perspectives","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:6887677","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6887677","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacol Res Perspect","raw_type":"Text"},{"id":"pmid:31832201","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31832201","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology research & perspectives","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:6e004fa2425f495d8f5c0c835326c642","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/6e004fa2425f495d8f5c0c835326c642","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Pharmacology Research & Perspectives, Vol 7, Iss 6, Pp n/a-n/a (2019)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1002/prp2.534","doi":"https://doi.org/10.1002/prp2.534","is_oa":true,"landing_page_url":"https://doi.org/10.1002/prp2.534","pdf_url":"https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prp2.534","source":{"id":"https://openalex.org/S2764487716","display_name":"Pharmacology Research & Perspectives","issn_l":"2052-1707","issn":["2052-1707"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology Research & Perspectives","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.8371999859809875,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1001886291","display_name":"Prevention of paclitaxel-induced peripheral neuropathy with nilotinib","funder_award_id":"R01CA238946","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G1930221042","display_name":"(9) Therapeutic strategies to mitigate toxicities of platinum-based therapeutics","funder_award_id":"R01CA215802","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G2564957956","display_name":"Tyrosine kinase inhibitors for the treatment of childhood AML","funder_award_id":"R01CA138744","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G3949345417","display_name":"Solute Carriers and Oxaliplatin Neurotoxicity","funder_award_id":"R01CA187176","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320309374","display_name":"Ohio State University","ror":"https://ror.org/00rs6vg23"},{"id":"https://openalex.org/F4320316230","display_name":"Pelotonia","ror":"https://ror.org/05jcvqz82"},{"id":"https://openalex.org/F4320318231","display_name":"Kanazawa University","ror":"https://ror.org/02hwp6a56"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"},{"id":"https://openalex.org/F4320337376","display_name":"NIH Clinical Center","ror":"https://ror.org/04vfsmv21"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2992248754.pdf","grobid_xml":"https://content.openalex.org/works/W2992248754.grobid-xml"},"referenced_works_count":38,"referenced_works":["https://openalex.org/W251703332","https://openalex.org/W1782655818","https://openalex.org/W1859254392","https://openalex.org/W1910813355","https://openalex.org/W1975712228","https://openalex.org/W1988144958","https://openalex.org/W1996237011","https://openalex.org/W1996850210","https://openalex.org/W2008137137","https://openalex.org/W2017634938","https://openalex.org/W2021046579","https://openalex.org/W2034886511","https://openalex.org/W2037527490","https://openalex.org/W2039887904","https://openalex.org/W2044837239","https://openalex.org/W2045783164","https://openalex.org/W2046076628","https://openalex.org/W2054334371","https://openalex.org/W2057024253","https://openalex.org/W2057499262","https://openalex.org/W2058549408","https://openalex.org/W2066189388","https://openalex.org/W2090664869","https://openalex.org/W2090891788","https://openalex.org/W2105590877","https://openalex.org/W2123859499","https://openalex.org/W2137075026","https://openalex.org/W2143835472","https://openalex.org/W2150097268","https://openalex.org/W2164124509","https://openalex.org/W2166241161","https://openalex.org/W2166721976","https://openalex.org/W2169337684","https://openalex.org/W2172232346","https://openalex.org/W2196483897","https://openalex.org/W2588008686","https://openalex.org/W2791781831","https://openalex.org/W2896392523"],"related_works":["https://openalex.org/W1038425005","https://openalex.org/W2058444707","https://openalex.org/W2018283978","https://openalex.org/W7100662050","https://openalex.org/W2057076082","https://openalex.org/W2164124509","https://openalex.org/W2154101477","https://openalex.org/W2588008686","https://openalex.org/W7037203168","https://openalex.org/W1596537940"],"abstract_inverted_index":{"Cytarabine":[0],"(Ara-C)":[1],"is":[2],"a":[3,76,103],"nucleoside":[4,61],"analog":[5],"used":[6],"in":[7,28,51,75,100],"the":[8,16,22,25,29,66,94,118,128],"treatment":[9],"of":[10,19,24,31,42,57,68,96,105,120,131],"acute":[11],"myeloid":[12],"leukemia":[13],"(AML).":[14],"Despite":[15],"many":[17],"years":[18],"clinical":[20],"use,":[21],"identity":[23],"transporter(s)":[26],"involved":[27],"disposition":[30,95],"Ara-C":[32,43,52,73,97,124],"remains":[33],"poorly":[34],"studied.":[35],"Previous":[36],"work":[37],"demonstrated":[38],"that":[39,93,126],"concurrent":[40],"administration":[41],"with":[44,72,102],"nitrobenzylmercaptopurine":[45],"ribonucleoside":[46],"(NBMPR)":[47],"causes":[48],"an":[49,69,121],"increase":[50],"plasma":[53],"levels,":[54],"suggesting":[55],"involvement":[56,119],"one":[58],"or":[59],"more":[60],"transporters.":[62],"Here,":[63],"we":[64],"confirmed":[65],"presence":[67],"NMBPR-mediated":[70],"interaction":[71,81],"resulting":[74],"2.5-fold":[77],"increased":[78],"exposure.":[79],"The":[80],"was":[82,98],"unrelated":[83],"to":[84],"altered":[85],"blood":[86],"cell":[87],"distribution,":[88],"and":[89,113],"subsequent":[90],"studies":[91,116],"indicated":[92],"unaffected":[99],"mice":[101],"deficiency":[104],"postulated":[106],"candidate":[107],"transporters,":[108],"including":[109],"ENT1,":[110],"OCTN1,":[111],"OATP1B2,":[112],"MATE1.":[114],"These":[115],"indicate":[117],"unknown":[122],"NBMPR-sensitive":[123],"transporter":[125],"impacts":[127],"pharmacokinetic":[129],"properties":[130],"this":[132],"clinically":[133],"important":[134],"agent.":[135]},"counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-12-13T00:00:00"}